

## Confidentiality Agreement

### SITC's Clinical Practice Guideline Draft

I understand that the information within the Society for Immunotherapy of Cancer (SITC) Multiple Myeloma Clinical Practice Guideline (CPG) draft that I am requesting is highly confidential and contains information that has not yet been made available to the general public (referenced hereafter as “confidential information” for the purposes of this agreement). Furthermore, I understand that while this information is being made available to me prior to public release, it is for the sole purpose of expert review and comment.

As a requirement for being allowed access to SITC's CPG draft prior to public release, I hereby agree that until it has been made public by SITC (“term”), I will regard each CPG draft and the associated information contained within as confidential.

With specific regard, and without limiting the generality of my agreement to maintain confidentiality of the draft, I understand that:

- During the term of this Agreement, I will not directly nor indirectly publish the confidential information included within the SITC CPG draft, nor disseminate or otherwise disclose, deliver, or make available the information to any third party for publication any time before the SITC CPG is made available to the public.
- I will not use, nor provide the information to another who may use the information included in the SITC CPG draft to trade in the securities of any issuer. Violation of this component of the agreement constitute a violation of federal or state securities laws and may subject me to civil or criminal liability.
- SITC does not guarantee – direct or implied – as to the accuracy or comprehensiveness of the CPG draft. SITC, its directors, members, and representatives do not hold any liability resulting from the information contained within or the use of the CPG draft.
- All comments received by the deadline will be reviewed by the Guideline Expert Panel leadership. Comments are advisory only and SITC is not obligated to make any suggested changes based on comments received. SITC will consider all submissions, but will not respond directly to individual commenters.

#### REQUESTING PARTY

To obtain access to SITC's “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of multiple myeloma v2.0,” I hereby agree to the terms of this Confidentiality Agreement.

NAME, DESIGNATION: \_\_\_\_\_

COMPANY/INSTITUTION: \_\_\_\_\_

TITLE: \_\_\_\_\_

ON BEHALF OF: \_\_\_\_\_

*If you are signing this NDA and are doing so not as the sole commenter, but on behalf of a team or group within your corporation or organization, you accept full responsibility for the terms herein (group or team name required).*

SIGNATURE: \_\_\_\_\_

DATE: \_\_\_\_\_

*Please email completed form to [scientificresources@sitcancer.org](mailto:scientificresources@sitcancer.org).*

*Once received, a copy of the guideline will be emailed to you within 1-2 business days for your review.*

***All comments must be received by 11:59 pm on Monday, January 5, 2026.***